Cargando…

The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment

BACKGROUND: Serial profiling of circulating tumor DNA (ctDNA) could reflect dynamic molecular changes in response to treatment and potentially predict impending disease progression (PD). Herein, we investigated the molecular factors and dynamic changes in ctDNA that can serve as predictors of surviv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Shenglin, Shi, Meiqi, Chen, Xueqin, Wang, Yong, Yang, Zhenhua, Lizaso, Analyn, Li, Min, Li, Haiyan, Zhang, Lu, Mao, Xinru, Xu, Xingxiang, Song, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867761/ https://www.ncbi.nlm.nih.gov/pubmed/33569316 http://dx.doi.org/10.21037/tlcr-20-371

Ejemplares similares

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
por: Liu, Lingli, et al.
Publicado: (2020)

Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report
por: Zhou, Yuling, et al.
Publicado: (2020)

The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report
por: Liu, Bin, et al.
Publicado: (2021)

Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma
por: Liu, Yutao, et al.
Publicado: (2020)

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer
por: Zeng, Liang, et al.
Publicado: (2020)

Erratum to Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients
por: Hu, Xingsheng, et al.
Publicado: (2020)

Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients
por: Hu, Xingsheng, et al.
Publicado: (2019)

Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
por: Kim, Chul, et al.
Publicado: (2021)

Does the natural product, honokiol, have value in the battle against osimertinib resistance?
por: Vallega, Karin A., et al.
Publicado: (2020)

Efficacy of afatinib in a HER2 amplification-positive endometrioid adenocarcinoma patient– a case report
por: Zhou, Li, et al.
Publicado: (2019)

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
por: Xing, Puyuan, et al.
Publicado: (2019)

The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis
por: Lu, Yuanyuan, et al.
Publicado: (2021)

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
por: Del Re, Marzia, et al.
Publicado: (2018)

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment
por: Su, Po‐Lan, et al.
Publicado: (2019)

Targeted sequencing identifies the mutational signature of double primary and metastatic malignancies: a case report
por: Rao, Chuangzhou, et al.
Publicado: (2019)

Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients
por: Li, Hang, et al.
Publicado: (2021)

Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma
por: Wintachai, Preawwalee, et al.
Publicado: (2021)

Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review
por: Fan, Gaowei, et al.
Publicado: (2017)

The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-Analysis
por: Basnet, Shiva, et al.
Publicado: (2016)

Prognostic value of circulating DNA levels in critically ill and trauma patients
por: Rodrigues Filho, Edison Moraes, et al.
Publicado: (2014)

Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method
por: Tang, Yuan, et al.
Publicado: (2020)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis
por: Tan, Guoqiang, et al.
Publicado: (2018)

Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report
por: Liu, Lian-Fang, et al.
Publicado: (2022)

A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients
por: Sun, Yi, et al.
Publicado: (2020)

Liquid‐based cell suspension of supraclavicular lymph node fine‐needle aspirate as an alternative specimen for NGS‐based genomic profiling in advanced lung cancer
por: Zhang, Xun, et al.
Publicado: (2020)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023)

Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis
por: Gao, Yunhe, et al.
Publicado: (2016)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma
por: Openshaw, Mark R., et al.
Publicado: (2020)

The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment
por: Sueoka‐Aragane, Naoko, et al.
Publicado: (2021)

High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy
por: Wu, Shibo, et al.
Publicado: (2020)

Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report
por: Xu, Li-Qing, et al.
Publicado: (2022)

Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Ye, Ke, et al.
Publicado: (2022)

Diagnostic value of circulating cell-free DNA for renal cell carcinoma: a meta-analysis
por: Li, Yong, et al.
Publicado: (2021)

Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
por: Wang, Li, et al.
Publicado: (2023)

Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report
por: Li, Zhaona, et al.
Publicado: (2019)

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer
por: Hadano, Naoto, et al.
Publicado: (2016)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f4nunb6b2giqv82i93lar7loeb